## Updated results from MONALEESA-2, a phase III trial of versus placebo plus letrozole in hormone receptor-posi breast cancer

Annals of Oncology 29, 1541-1547 DOI: 10.1093/annonc/mdy155

**Citation Report** 

| #  | Article                                                                                                                                                                                                                                                                                          | IF   | CITATIONS |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 1  | ABC4 Consensus: Assessment by a German Group of Experts. Breast Care, 2018, 13, 48-58.                                                                                                                                                                                                           | 1.4  | 7         |
| 2  | Health-related quality of life of postmenopausal women with hormone receptor-positive, human<br>epidermal growth factor receptor 2-negative advanced breast cancer treated with<br>ribociclib + letrozole: results from MONALEESA-2. Breast Cancer Research and Treatment, 2018, 170,<br>535-545 | 2.5  | 68        |
| 4  | Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: study protocol for a randomized controlled trial. BMC Cancer, 2018, 18, 1146.                                                                                         | 2.6  | 36        |
| 5  | Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591881559.                                                                                   | 3.2  | 5         |
| 6  | Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591880961.                                      | 3.2  | 44        |
| 7  | Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 3-11.                                                                                                     | 1.1  | 4         |
| 8  | Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone<br>receptor positive HER2â€nonâ€amplified metastatic breast cancer. Asia-Pacific Journal of Clinical<br>Oncology, 2018, 14, 12-21.                                                                   | 1.1  | 1         |
| 9  | CDK4-6 inhibitors in breast cancer: current status and future development. Expert Opinion on Drug<br>Metabolism and Toxicology, 2018, 14, 1-16.                                                                                                                                                  | 3.3  | 23        |
| 10 | CDK4/6 inhibitors as neoadjuvant treatment in breast cancer—what can we learn?. Annals of<br>Oncology, 2018, 29, 2274-2278.                                                                                                                                                                      | 1.2  | 4         |
| 11 | Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. New England Journal of<br>Medicine, 2018, 379, 1926-1936.                                                                                                                                                           | 27.0 | 805       |
| 12 | Ribociclib in premenopausal women with advanced breast cancer. Lancet Oncology, The, 2018, 19, 850-852.                                                                                                                                                                                          | 10.7 | 2         |
| 13 | Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line<br>treatment of post-menopausal women with HR+/HER2â^' advanced or metastatic breast cancer. Current<br>Medical Research and Opinion, 2018, 34, 2143-2150.                                 | 1.9  | 7         |
| 14 | CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials. Breast Cancer Research and Treatment, 2018, 172, 9-21.                                                                                          | 2.5  | 52        |
| 15 | Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Redrawing the Lines. Current<br>Oncology, 2018, 25, 131-141.                                                                                                                                                                  | 2.2  | 31        |
| 16 | Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic<br>Breast Cancer. Frontiers in Oncology, 2018, 8, 308.                                                                                                                                           | 2.8  | 62        |
| 17 | The role of abemaciclib in treatment of advanced breast cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591877692.                                                                                                                                                             | 3.2  | 14        |
| 18 | 4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017.<br>Geburtshilfe Und Frauenheilkunde, 2018, 78, 469-480.                                                                                                                                       | 1.8  | 3         |
| 22 | Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women. American Journal of Health-System Pharmacy, 2019, 76, 1183-1202.                                                                                                                     | 1.0  | 21        |

TATION REPO

| #  | Article                                                                                                                                                                                                                                                                                                                                                                                           | IF                | CITATIONS          |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|--------------------|
| 23 | First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis. Clinical Breast Cancer, 2019, 19, e701-e716.                                                                                                                                                                                                                                | 2.4               | 10                 |
| 24 | MONALEESA clinical program: a review of ribociclib use in different clinical settings. Future Oncology, 2019, 15, 2673-2686.                                                                                                                                                                                                                                                                      | 2.4               | 21                 |
| 25 | Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast<br>Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials.<br>Frontiers in Oncology, 2019, 9, 510.                                                                                                                                                               | 2.8               | 49                 |
| 26 | PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy. Breast Cancer Research and Treatment, 2019, 177, 659-667.                                                                                                                                                                           | 2.5               | 17                 |
| 27 | Somatic BRCA2 Mutation-Positive Concurrent Accessory Male Breast Cancer (BC) and Non-Small Cell<br>Lung Cancer (NSCLC): Excellent Efficacy of Palbociclib, Fulvestrant and Leuprolide in<br>Platinum-Exposed and Endocrine-Refractory BC Associated with Cyclin D1 and FGFR1 Amplification and<br>of Carboplatin, Paclitaxel and Radiation in NSCLC. Case Reports in Oncology, 2019, 12, 494-499. | 0.7               | 5                  |
| 28 | Achieving Improved Survival Outcomes in Advanced Breast Cancer. New England Journal of Medicine, 2019, 381, 371-372.                                                                                                                                                                                                                                                                              | 27.0              | 15                 |
| 29 | Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors. Frontiers in Pharmacology, 2019, 10, 1235.                                                                                                                                                                                                               | 3.5               | 24                 |
| 30 | Homeopathic supportive care protocol for oral inhibitors of cyclin dependent kinases 4 and 6 (CDK) Tj ETQq1 10, e69-e73.                                                                                                                                                                                                                                                                          | 1 0.784314<br>0.1 | rgBT /Overloc<br>1 |
| 31 | Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.<br>Japanese Journal of Clinical Oncology, 2019, 49, 993-998.                                                                                                                                                                                                                                 | 1.3               | 23                 |
| 32 | Comprehensive molecular profiling of extrahepatic cholangiocarcinoma in Chinese population and potential targets for clinical practice. Hepatobiliary Surgery and Nutrition, 2019, 8, 615-622.                                                                                                                                                                                                    | 1.5               | 15                 |
| 33 | Update Breast Cancer 2019 Part 5 – Diagnostic and Therapeutic Challenges of New, Personalised<br>Therapies in Patients with Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2019, 79,<br>1090-1099.                                                                                                                                                                                     | 1.8               | 16                 |
| 34 | CDK4/6 inhibitors in advanced breast cancer, what is beyond?. Oncology Reviews, 2019, 13, 416.                                                                                                                                                                                                                                                                                                    | 1.8               | 6                  |
| 35 | Prognostic relevance of DNA damage and repair biomarkers in elderly patients with<br>hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from<br>the real-world setting. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591985319.                                                                                                              | 3.2               | 2                  |
| 36 | Different Cardiotoxicity of Palbociclib and Ribociclib in Breast Cancer: Gene Expression and<br>Pharmacological Data Analyses, Biological Basis, and Therapeutic Implications. BioDrugs, 2019, 33,<br>613-620.                                                                                                                                                                                    | 4.6               | 23                 |
| 37 | Can CDK4/6 inhibitors cause fatal lung injury?. Expert Review of Anticancer Therapy, 2019, 19, 917-919.                                                                                                                                                                                                                                                                                           | 2.4               | 29                 |
| 38 | Addressing physician barriers to administering cyclin-dependent kinases 4 and 6 inhibitors in first-line treatment of hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer. Cancer Management and Research, 2019, Volume 11, 513-524.                                                                                                              | 1.9               | 5                  |
| 39 | Cyclin-dependent kinase 4/6 inhibitors: what have we learnt across studies, therapy situations and substances. Current Opinion in Obstetrics and Gynecology, 2019, 31, 56-66.                                                                                                                                                                                                                     | 2.0               | 9                  |
| 40 | The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics. Oncology and Therapy, 2019, 7, 1-32.                                                                                                                                                                                                                                                                               | 2.6               | 19                 |

| #  | Article                                                                                                                                                                                                                                                               | IF   | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 41 | Cardiotoxicities of Modern Treatments in Breast Cancer. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 34.                                                                                                                                           | 0.9  | 2         |
| 42 | Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology. Expert Review of Anticancer Therapy, 2019, 19, 569-587.                                                                              | 2.4  | 21        |
| 44 | QT Interval Prolongation Associated With Cytotoxic and Targeted Cancer Therapeutics. Current<br>Treatment Options in Oncology, 2019, 20, 55.                                                                                                                          | 3.0  | 24        |
| 45 | Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. New England Journal of Medicine, 2019, 381, 307-316.                                                                                                                                        | 27.0 | 656       |
| 46 | Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer:<br>a multidisciplinary approach is the key to success. Breast Cancer Research and Treatment, 2019, 176,<br>483-494.                                             | 2.5  | 28        |
| 47 | PALOMA-3 clinical trial: is there a significant benefit in overall survival for breast cancer? Is it worth it?. Future Oncology, 2019, 15, 1407-1410.                                                                                                                 | 2.4  | 4         |
| 48 | The Role of CDK4/6 Inhibitors in Breast Cancer. Current Treatment Options in Oncology, 2019, 20, 52.                                                                                                                                                                  | 3.0  | 39        |
| 49 | Role of Liquid Biopsy in Clinical Decision-Making for Breast Cancer. Current Breast Cancer Reports, 2019, 11, 52-66.                                                                                                                                                  | 1.0  | 1         |
| 50 | Concurrent radiotherapy with palbociclib or ribociclib for metastatic breast cancer patients:<br>Preliminary assessment of toxicity. Breast, 2019, 46, 70-74.                                                                                                         | 2.2  | 49        |
| 51 | An analysis of available biomarker data for targeting cyclin-dependent kinases 4 and 6 (CDK4/6) in breast cancer. Expert Review of Precision Medicine and Drug Development, 2019, 4, 129-138.                                                                         | 0.7  | 1         |
| 52 | Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer. International Journal of Molecular<br>Sciences, 2019, 20, 2353.                                                                                                                                     | 4.1  | 24        |
| 53 | Dependency of Cholangiocarcinoma on Cyclin D–Dependent Kinase Activity. Hepatology, 2019, 70,<br>1614-1630.                                                                                                                                                           | 7.3  | 22        |
| 54 | Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591983386.                                                                                     | 3.2  | 39        |
| 55 | Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy. Breast Cancer Research and Treatment, 2019, 176, 429-434.                                                                              | 2.5  | 51        |
| 56 | Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591982771.                                                                           | 3.2  | 38        |
| 57 | Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer. Breast Cancer Research and Treatment, 2019, 175, 775-779.                                                               | 2.5  | 34        |
| 58 | Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers.<br>Endocrine Connections, 2019, 8, R10-R26.                                                                                                                         | 1.9  | 33        |
| 59 | Palbociclib or Ribociclib in First-Line Treatment in Patients With Hormone Receptor–Positive/Human<br>Epidermal Receptor 2–Negative Advanced or Metastatic Breast Cancer? A Perspective Based on<br>Pharmacologic Costs. Clinical Breast Cancer, 2019, 19, e519-e521. | 2.4  | 5         |

| #                    | Article                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | IF                              | CITATIONS               |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|-------------------------|
| 62                   | Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor<br>As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2,<br>MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials. Cancers, 2019, 11, 1661.                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 3.7                             | 48                      |
| 63                   | The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive<br>Biomarker of Response to Endocrine Therapy. Cancers, 2019, 11, 1894.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 3.7                             | 53                      |
| 64                   | Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of squamous cell carcinoma of the head and neck. Current Opinion in Oncology, 2019, 31, 122-130.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 2.4                             | 18                      |
| 65                   | Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid<br>Leukemia. Frontiers in Oncology, 2019, 9, 1205.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 2.8                             | 29                      |
| 66                   | A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with<br>Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer. Cancer Discovery, 2019, 9, 354-369.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 9.4                             | 104                     |
| 67                   | Ribociclib in HR+/HER2â^' Advanced or Metastatic Breast Cancer Patients. Annals of Pharmacotherapy,<br>2019, 53, 501-509.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 1.9                             | 15                      |
| 68                   | Why upfront use of CDK inhibitors for the treatment of advanced breast cancer may be wasteful, and how we can increase their value. Breast, 2019, 43, 81-84.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 2.2                             | 3                       |
| 69                   | SEOM clinical guidelines in advanced and recurrent breast cancer (2018). Clinical and Translational Oncology, 2019, 21, 31-45.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 2.4                             | 14                      |
| 70                   | Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs. Pharmacological<br>Research, 2019, 139, 471-488.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 7.1                             | 270                     |
| 71                   | Targeting CDK4/6 pathways and beyond in breast cancer. Breast, 2019, 43, 8-17.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 2.2                             | 22                      |
| 72                   | Targeted therapy for breast cancer in older patients. Journal of Geriatric Oncology, 2020, 11, 380-388.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 1.0                             | 9                       |
| 73                   | Complete Clinical Response in Locally Advanced Metastatic de novo Breast Cancer after Front-Line<br>Treatment with Ribociclib/Letrozole within the RIBANNA Study. Breast Care, 2020, 15, 289-293.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 1.4                             | 2                       |
| 74                   | Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                 |                         |
|                      | patient-proxy empowerment. Annals of Palliative Medicine, 2020, 9, 1296-1306.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 1.2                             | 5                       |
| 75                   | Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6<br>Inhibition and Endocrine Therapy in Advanced HR+/HER2â <sup>-2</sup> Breast Cancer. Clinical Breast Cancer, 2020, 20, 1-11.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | <b>1.2</b><br>2.4               | 5<br>20                 |
| 75<br>76             | <ul> <li>Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6<br/>Inhibition and Endocrine Therapy in Advanced HR+/HER2â<sup>-*</sup> Breast Cancer. Clinical Breast Cancer, 2020, 20, 1-11.</li> <li>CDK4/6 inhibitors in breast cancer – from <i>inÂvitro </i> models to clinical trials. Acta OncolÃ<sup>3</sup>gica, 2020, 59, 219-232.</li> </ul>                                                                                                                                                                                                                                                                                                                                                         | 1.2<br>2.4<br>1.8               | 5<br>20<br>8            |
| 75<br>76<br>77       | <ul> <li>Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6<br/>Inhibition and Endocrine Therapy in Advanced HR+/HER2â<sup>°</sup> Breast Cancer. Clinical Breast Cancer, 2020, 20, 1-11.</li> <li>CDK4/6 inhibitors in breast cancer – from <i>inÂvitro </i> models to clinical trials. Acta OncolÃ<sup>3</sup>gica, 2020, 59, 219-232.</li> <li>Phase II study of Radiumâ€223 dichloride combined with hormonal therapy for hormone receptorâ€positive, boneâ€dominant metastatic breast cancer. Cancer Medicine, 2020, 9, 1025-1032.</li> </ul>                                                                                                                                                           | 1.2<br>2.4<br>1.8<br>2.8        | 5<br>20<br>8<br>19      |
| 75<br>76<br>77<br>78 | <ul> <li>Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6<br/>Inhibition and Endocrine Therapy in Advanced HR+/HER2â<sup>2</sup> Breast Cancer. Clinical Breast Cancer, 2020, 20, 1-11.</li> <li>CDK4/6 inhibitors in breast cancer – from <i>inÂvitro </i>models to clinical trials. Acta Oncológica, 2020, 59, 219-232.</li> <li>Phase II study of Radiumâ€223 dichloride combined with hormonal therapy for hormone receptorâ€positive, boneâ€dominant metastatic breast cancer. Cancer Medicine, 2020, 9, 1025-1032.</li> <li>Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity. Future Oncology, 2020, 16, 129-145.</li> </ul> | 1,2<br>2.4<br>1.8<br>2.8<br>2.4 | 5<br>20<br>8<br>19<br>5 |

| #  | Article                                                                                                                                                                                                                                                                                      | IF   | CITATIONS |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 80 | CDK4/6 inhibitors plus endocrine therapy improve overall survival in advanced HR+/HER2â^' breast cancer: A metaâ€analysis of randomized controlled trials. Breast Journal, 2020, 26, 1439-1443.                                                                                              | 1.0  | 12        |
| 81 | Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. New England Journal of<br>Medicine, 2020, 382, 514-524.                                                                                                                                                         | 27.0 | 482       |
| 82 | The impact of new systemic therapies on survival and time on hormonal treatment in hormone<br>receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: A<br>populationâ€based study in British Columbia from 2003 to 2013. Cancer, 2020, 126, 971-977. | 4.1  | 3         |
| 83 | Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial. Breast, 2020, 49, 55-62.                                                                                                                                           | 2.2  | 49        |
| 84 | Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone<br>Receptor–Positive Metastatic Breast Cancer. JAMA Network Open, 2020, 3, e2020312.                                                                                                       | 5.9  | 48        |
| 85 | Can we cure oligometastatic disease? A practical point of view. Current Opinion in Oncology, 2020, 32, 568-574.                                                                                                                                                                              | 2.4  | 5         |
| 86 | Prevention, Detection, and Management of Heart Failure in Patients Treated for Breast Cancer.<br>Current Heart Failure Reports, 2020, 17, 397-408.                                                                                                                                           | 3.3  | 12        |
| 87 | Developing themes in targeted therapies for hormone receptor–positive breast cancer. Current<br>Opinion in Endocrine and Metabolic Research, 2020, 15, 15-23.                                                                                                                                | 1.4  | 0         |
| 88 | Efficacy and safety of selective cyclin-dependent kinases 4/6 inhibitors in hormone-receptor-positive,<br>HER2-negative advanced breast cancer – results from a real-world setting. Cancer Treatment and<br>Research Communications, 2020, 25, 100201.                                       | 1.7  | 4         |
| 89 | Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in<br>metastatic breast cancer: A network meta-analysis. Cancer Treatment Reviews, 2020, 90, 102086.                                                                                      | 7.7  | 29        |
| 90 | Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study. Breast, 2020, 54, 148-154.                                                                                                                                       | 2.2  | 25        |
| 91 | Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors<br>Palbociclib, Ribociclib, and Abemaciclib. Clinical Pharmacokinetics, 2020, 59, 1501-1520.                                                                                                | 3.5  | 43        |
| 92 | ABC4 Consensus: First Latin American Meeting—Assessment, Comments, and Application of Its<br>Recommendations. JCO Global Oncology, 2020, 6, 819-827.                                                                                                                                         | 1.8  | 2         |
| 93 | Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer. Frontiers in Pharmacology, 2020, 11, 580251.                                                                                                                                                                             | 3.5  | 38        |
| 94 | Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy<br>Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer. Journal of Cancer, 2020,<br>11, 7127-7136.                                                                    | 2.5  | 11        |
| 95 | Evaluation of Absolute Oral Bioavailability and Bioequivalence of Ribociclib, a Cyclinâ€Dependent Kinase<br>4/6 Inhibitor, in Healthy Subjects. Clinical Pharmacology in Drug Development, 2020, 9, 855-866.                                                                                 | 1.6  | 11        |
| 96 | Ribociclib therapy in peritoneal carcinomatosis secondary to HER2â€negative metastatic breast cancer: A clinical case with a positive outcome. Breast Journal, 2020, 26, 1808-1810.                                                                                                          | 1.0  | 0         |
| 97 | Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer. Future Oncology, 2020, 16, 2763-2778.                                                                                                                                                                  | 2.4  | 8         |

|     |                                                                                                                                                                                                                                                                                                   | CITATION REPORT                      |      |           |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|------|-----------|
| #   | Article                                                                                                                                                                                                                                                                                           |                                      | IF   | CITATIONS |
| 98  | Endocrine-Resistant Breast Cancer: Mechanisms and Treatment. Breast Care, 2020, 15, 3                                                                                                                                                                                                             | 347-354.                             | 1.4  | 46        |
| 99  | Health-related quality of life in premenopausal women with hormone-receptor-positive, H<br>advanced breast cancer treated with ribociclib plus endocrine therapy: results from a pha<br>randomized clinical trial (MONALEESA-7). Therapeutic Advances in Medical Oncology, 20<br>175883592094306. | IER2-negative<br>ase III<br>220, 12, | 3.2  | 44        |
| 100 | Endocrine therapy combined with targeted therapy in hormone receptor-positive metast cancer. Chinese Medical Journal, 2020, 133, 2338-2345.                                                                                                                                                       | atic breast                          | 2.3  | 8         |
| 101 | Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advances cancer: systematic review and network meta-analysis. ESMO Open, 2020, 5, e000842.                                                                                                                          | ced breast                           | 4.5  | 16        |
| 102 | Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer. Drugs, 2020,                                                                                                                                                                                                               | 80, 1685-1697.                       | 10.9 | 72        |
| 103 | Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors. International Journal of Molecul 2020, 21, 6479.                                                                                                                                                                                        | ar Sciences,                         | 4.1  | 71        |
| 104 | Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Thera<br>Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. International Journal<br>Sciences, 2020, 21, 6400.                                                                                  | py in<br>of Molecular                | 4.1  | 50        |
| 105 | POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormoneÂreceptor-positive advanced breast cancer. Future Oncology, 2020, 16, 2475-2                                                                                                                         | 485.                                 | 2.4  | 9         |
| 106 | Efficacy and safety of cyclin dependent kinases 4/6 inhibitors in the treatment of metast cancer: a real-world experience. Acta Oncológica, 2020, 59, 1382-1387.                                                                                                                                  | atic breast                          | 1.8  | 11        |
| 107 | Phase II randomized trial of a non-steroidal mouth wash for prevention and treatment of women with hormone receptor positive breast cancer treated with everolimus. Therapeu in Medical Oncology, 2020, 12, 175883592096725.                                                                      | stomatitis in<br>tic Advances        | 3.2  | 0         |
| 108 | Optimizing care for younger women with hormone receptorâ€positive, HER2â€negative cancer. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 3-14.                                                                                                                                              | metastatic breast                    | 1.1  | 3         |
| 109 | Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Dise<br>Progression on a CDK4/6 Inhibitor?. Current Oncology Reports, 2020, 22, 57.                                                                                                                                | ase                                  | 4.0  | 26        |
| 110 | Therapy after cyclinâ€dependent kinase inhibition in metastatic hormone receptorâ€pos<br>Resistance mechanisms and novel treatment strategies. Cancer, 2020, 126, 3400-3416.                                                                                                                      | itive breast cancer:                 | 4.1  | 19        |
| 111 | What's the Price? Toxicities of Targeted Therapies in Breast Cancer Care. American S<br>Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 202                                                                                                                       | ociety of Clinical<br>0, 40, 55-70.  | 3.8  | 13        |
| 112 | Advances in endocrine and targeted therapy for hormone-receptor-positive, human epide<br>factor receptor 2-negative advanced breast cancer. Chinese Medical Journal, 2020, 133,                                                                                                                   | ermal growth<br>1099-1108.           | 2.3  | 17        |
| 113 | Potential through simplicity: thymidine kinase-1 as a biomarker for CDK4/6 inhibitors. Bri<br>of Cancer, 2020, 123, 176-177.                                                                                                                                                                      | tish Journal                         | 6.4  | 4         |
| 114 | Preclinical Activity of Ribociclib in Squamous Cell Carcinoma of the Head and Neck. Mole<br>Therapeutics, 2020, 19, 777-789.                                                                                                                                                                      | cular Cancer                         | 4.1  | 17        |
| 115 | Genome-Driven Therapy for Chemotherapy-Resistant Metastatic CDK6-Amplified Osteos<br>Precision Oncology, 2020, 4, 498-504.                                                                                                                                                                        | arcoma. JCO                          | 3.0  | 2         |

| #   | Article                                                                                                                                                                                                                                                                                                                                                                                          | IF  | Citations |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 116 | Ribociclib-Induced Radiation Recall Dermatitis Following Stereotactic Body Radiation Therapy: Case<br>Report and Literature Review. Hematology/ Oncology and Stem Cell Therapy, 2021, 14, 353-354.                                                                                                                                                                                               | 0.9 | 5         |
| 117 | Overall Survival of CDK4/6-Inhibitor–Based Treatments in Clinically Relevant Subgroups of Metastatic<br>Breast Cancer: Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 2020, 112,<br>1089-1097.                                                                                                                                                                   | 6.3 | 59        |
| 118 | Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology.<br>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical<br>Oncology Meeting, 2020, 40, e292-e308.                                                                                                                                                             | 3.8 | 3         |
| 119 | <p>Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer</p> . Cancer<br>Management and Research, 2020, Volume 12, 3477-3487.                                                                                                                                                                                                                                                       | 1.9 | 40        |
| 120 | Breakthrough therapy-designated oncology drugs: are they rightfully criticized?. Drug Discovery<br>Today, 2020, 25, 1580-1584.                                                                                                                                                                                                                                                                   | 6.4 | 3         |
| 121 | Retinoblastoma protein expression and its predictors in triple-negative breast cancer. Npj Breast<br>Cancer, 2020, 6, 19.                                                                                                                                                                                                                                                                        | 5.2 | 23        |
| 122 | Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?.<br>Expert Review of Anticancer Therapy, 2020, 20, 563-573.                                                                                                                                                                                                                                             | 2.4 | 2         |
| 123 | Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0233571.                                                                                                             | 2.5 | 16        |
| 124 | Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific<br>perspective and practical management guide on the use of CDK4/6 inhibitors. Current Medical<br>Research and Opinion, 2020, 36, 1363-1373.                                                                                                                                                   | 1.9 | 5         |
| 125 | An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data. Pharmacology Research and Perspectives, 2020, 8, e00599.                                                                                                                                                                                        | 2.4 | 17        |
| 126 | <p>Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers:<br/>Current Perspectives</p> . Breast Cancer: Targets and Therapy, 2020, Volume 12, 45-56.                                                                                                                                                                                                             | 1.8 | 15        |
| 127 | Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments. Medical<br>Sciences (Basel, Switzerland), 2020, 8, 18.                                                                                                                                                                                                                                                    | 2.9 | 72        |
| 128 | Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors. Breast Cancer Research and Treatment, 2020, 181, 199-209.                                                                                                                                                                              | 2.5 | 19        |
| 129 | The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first<br>and subsequent-lines after progression or relapse during previous endocrine therapy in patients with<br>hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic<br>breast cancer. Journal of Oncology Pharmacy Practice, 2020, 26, 1486-1491. | 0.9 | 12        |
| 130 | Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application. PLoS ONE, 2020, 15, e0228822.                                                                                                                                                                                                                            | 2.5 | 26        |
| 131 | A multidisciplinary expert opinion on CINV and RINV, unmet needs and practical real-life approaches.<br>Expert Opinion on Drug Safety, 2020, 19, 187-204.                                                                                                                                                                                                                                        | 2.4 | 5         |
| 132 | High-Dose Toremifene as a Promising Candidate Therapy for Hormone Receptor-Positive Metastatic<br>Breast Cancer with Secondary Resistance to Aromatase Inhibitors. International Journal of Breast<br>Cancer, 2020, 2020, 1-7.                                                                                                                                                                   | 1.2 | 2         |
| 133 | Cyclin-dependent kinase 4/6 inhibitor in combination with endocrine therapy versus endocrine therapy only for advanced breast cancer: a systematic review and meta-analysis. Translational Cancer Research, 2020, 9, 657-668.                                                                                                                                                                    | 1.0 | 3         |

| #   | Article                                                                                                                                                                                                                                                                                                                                                            | IF  | CITATIONS |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 134 | Biologic therapy for advanced breast cancer: recent advances and future directions. Expert Opinion on Biological Therapy, 2020, 20, 1009-1024.                                                                                                                                                                                                                     | 3.1 | 23        |
| 135 | Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients<br>with <i>AKT1</i> E17K-Mutant, ER-Positive Metastatic Breast Cancer. Clinical Cancer Research, 2020, 26,<br>3947-3957.                                                                                                                                      | 7.0 | 54        |
| 136 | Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor–Positive<br>Breast Cancer. Clinical Cancer Research, 2020, 26, 4120-4134.                                                                                                                                                                                                  | 7.0 | 65        |
| 137 | Ribociclib-Induced Pneumonitis: A Case Report. Breast Care, 2021, 16, 307-311.                                                                                                                                                                                                                                                                                     | 1.4 | 5         |
| 138 | Evaluating the Clinical Utility of Circulating Tumor Cells in Metastatic Breast Cancer—Is Not Worse<br>Good Enough?. JAMA Oncology, 2021, 7, 30.                                                                                                                                                                                                                   | 7.1 | 1         |
| 139 | Costâ€effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore. Cancer Reports, 2021, 4, e1308.                                                                                                                                                                                                           | 1.4 | 7         |
| 140 | PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients. Pharmacological Research, 2021, 163, 105241.                                                                                                                                                                             | 7.1 | 23        |
| 141 | RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer. British Journal of Cancer, 2021, 124, 191-206.                                                                                                                                                                                                                                        | 6.4 | 16        |
| 142 | CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis. Expert Review of Anticancer Therapy, 2021, 21, 283-298.                                                                                                                                                                    | 2.4 | 39        |
| 143 | CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer. Cancer Treatment Reviews, 2021, 93, 102136.                                                                                                                                                               | 7.7 | 25        |
| 144 | Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth<br>Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review. Advances in Therapy, 2021,<br>38, 109-136.                                                                                                                                                 | 2.9 | 23        |
| 145 | SOLAR1s: alpelisib returns to earth?. Annals of Oncology, 2021, 32, 129-132.                                                                                                                                                                                                                                                                                       | 1.2 | 2         |
| 146 | Enhanced toxicity with CDK 4/6 inhibitors and palliative radiotherapy: Non-consecutive case series and review of the literature. Translational Oncology, 2021, 14, 100939.                                                                                                                                                                                         | 3.7 | 18        |
| 147 | Ribociclib plus fulvestrant in the treatment of breast cancer. Expert Review of Anticancer Therapy, 2021, 21, 93-106.                                                                                                                                                                                                                                              | 2.4 | 9         |
| 148 | Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor<br>(Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer. Clinical Cancer Research, 2021, 27, 418-428.                                                                                                                                                        | 7.0 | 16        |
| 149 | First Experiences with Alpelisib in Clinical Routine: Case Reports from a German Breast Center. Breast<br>Care, 2021, 16, 129-134.                                                                                                                                                                                                                                 | 1.4 | 3         |
| 150 | Treatment of Luminal Metastatic Breast Cancer beyond CDK4/6 Inhibition: Is There a Standard of Care in Clinical Practice?. Breast Care, 2021, 16, 115-128.                                                                                                                                                                                                         | 1.4 | 10        |
| 151 | Cost-effectiveness of ribociclib plus letrozole <i>versus</i> palbociclib plus letrozole or letrozole as<br>monotherapy in first-line treatment of postmenopausal women with HR+/HER2â <sup>2</sup> locally advanced or<br>metastatic breast cancer: a Brazilian private payer perspective. Therapeutic Advances in Medical<br>Oncolomy, 2021, 13, 175883592110005 | 3.2 | 6         |

| # |         |  |
|---|---------|--|
| # | ARTICLE |  |

| #   | Article                                                                                                                                                                                                                                                                                      | IF  | Сі |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----|
| 152 | Cardiovascular Oncologic Emergencies. , 2021, , 269-290.                                                                                                                                                                                                                                     |     | 0  |
| 153 | CDK4/6 inhibitor plus endocrine therapy for hormone receptorâ€positive, HER2â€negative metastatic breast cancer: The new standard of care. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 3-14.                                                                                        | 1.1 | 11 |
| 154 | CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced<br>Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives.<br>Cancers, 2021, 13, 332.                                                                   | 3.7 | 35 |
| 156 | Nexus between PI3K/AKT and Estrogen Receptor Signaling in Breast Cancer. Cancers, 2021, 13, 369.                                                                                                                                                                                             | 3.7 | 35 |
| 157 | Frontiers in HER2-positive breast cancer in 2020. Current Opinion in Obstetrics and Gynecology, 2021, 33, 48-52.                                                                                                                                                                             | 2.0 | 1  |
| 159 | Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy. Npj Breast Cancer, 2021, 7, 8.                                                                                                                                                | 5.2 | 14 |
| 160 | Clinical application of circulating tumor DNA in breast cancer. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1431-1442.                                                                                                                                                      | 2.5 | 5  |
| 161 | Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR). BMC Cancer, 2021, 21, 303.                                                                                                                                                                                | 2.6 | 13 |
| 162 | Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives. Therapeutics and Clinical Risk Management, 2021, Volume 17, 193-207.                                                                                                        | 2.0 | 34 |
| 163 | Significant impact of circulating tumour DNA mutations on survival in metastatic breast cancer patients. Scientific Reports, 2021, 11, 6761.                                                                                                                                                 | 3.3 | 16 |
| 164 | Pharmacokinetics of Ribociclib in Subjects With Hepatic Impairment. Journal of Clinical Pharmacology, 2021, 61, 1001-1009.                                                                                                                                                                   | 2.0 | 6  |
| 165 | The Way of the Future: Personalizing Treatment Plans Through Technology. American Society of<br>Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41,<br>12-23.                                                                                 | 3.8 | 8  |
| 166 | Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2â^' metastatic breast cancer. Breast Cancer Research and Treatment, 2021, 188, 799-809.                                                                                                                      | 2.5 | 11 |
| 167 | CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer. JCO Precision Oncology, 2021, 5, 676-686.                                                                                                                                                                         | 3.0 | 20 |
| 168 | Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL. Annals of Oncology, 2021, 32, 488-499. | 1.2 | 69 |
| 169 | Efficacy and Safety of CDK4/6 Inhibitors Combined with Endocrine Therapy in HR+/HER-2â^' ABC Patients:<br>A Systematic Review and Meta-Analysis. Cancer Investigation, 2021, 39, 369-378.                                                                                                    | 1.3 | 7  |
| 170 | Challenge of Incorporating New Drugs for Breast Cancer in Brazil: A Proposed Framework for<br>Improving Access to Innovative Therapies. JCO Global Oncology, 2021, 7, 474-485.                                                                                                               | 1.8 | 2  |

Adjuvant cyclinâ $\in$ dependent kinase 4/6 inhibition in hormone receptorâ $\in$  positive breast cancer: One Monarch to rule them all?. Cancer, 2021, 127, 3302-3309.

| #   | Article                                                                                                                                                                                                                                                                              | IF   | CITATIONS |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 173 | Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular<br>Mechanisms. Frontiers in Oncology, 2021, 11, 651541.                                                                                                                              | 2.8  | 8         |
| 174 | Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast<br>Cancer. Current Oncology, 2021, 28, 1803-1822.                                                                                                                                        | 2.2  | 24        |
| 175 | Liquid Biopsy: A New Tool for Overcoming CDKi Resistance Mechanisms in Luminal Metastatic Breast<br>Cancer. Journal of Personalized Medicine, 2021, 11, 407.                                                                                                                         | 2.5  | 3         |
| 176 | Changes in Overall Survival over Time for Patients with de novo Metastatic Breast Cancer. Cancers, 2021, 13, 2650.                                                                                                                                                                   | 3.7  | 11        |
| 177 | Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III<br>Studies. Journal of Clinical Oncology, 2021, 39, 1458-1467.                                                                                                                      | 1.6  | 73        |
| 178 | Advances in Therapy for Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2<br>(HER2)-Negative Advanced Breast Cancer Patients Who Have Experienced Progression After Treatment<br>with CDK4/6 Inhibitors. OncoTargets and Therapy, 2021, Volume 14, 2929-2939. | 2.0  | 3         |
| 179 | Don't let it disappear: new opportunities to prolong the life of HR+ HER2- advanced breast cancer<br>patients. Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online).<br>January 28th, 2021. Journal of Modern Oncology, 2021, 23, 53-60.          | 0.3  | 0         |
| 180 | Optimal integration of CDK4/6 inhibitors for treatment of hormone receptor-positive metastatic breast cancer. Practical Oncology, 2021, 4, 11-18.                                                                                                                                    | 0.1  | 0         |
| 181 | First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study. Breast, 2021, 57, 104-112.                                                                                                                | 2.2  | 14        |
| 182 | First-Line Treatment with a Cyclin-Dependent Kinase 4/6 Inhibitor Plus an Aromatase Inhibitor for<br>Metastatic Breast Cancer in Alberta. Current Oncology, 2021, 28, 2270-2280.                                                                                                     | 2.2  | 4         |
| 183 | Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in<br>hormone receptor-positive, HER2-negative advanced breast cancer. British Journal of Cancer, 2021, 125,<br>679-686.                                                            | 6.4  | 31        |
| 184 | Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications: A Scientific Statement From the American Heart Association. Circulation Genomic and Precision Medicine, 2021, 14, e000082.    | 3.6  | 55        |
| 185 | Oligometastatic Breast Cancer: How to Manage It?. Journal of Personalized Medicine, 2021, 11, 532.                                                                                                                                                                                   | 2.5  | 8         |
| 186 | Role of the Combination of Cyclin-Dependent Kinase Inhibitors (CDKI) and Radiotherapy (RT) in the Treatment of Metastatic Breast Cancer (MBC): Advantages and Risks in Clinical Practice. Frontiers in Oncology, 2021, 11, 643155.                                                   | 2.8  | 13        |
| 187 | Post San Antonio update—my top three abstracts!. Memo - Magazine of European Medical Oncology,<br>2021, 14, 244-246.                                                                                                                                                                 | 0.5  | 1         |
| 188 | Predicting optimal treatment regimens for patients with HR+/HER2-Âbreast cancer using machine<br>learning based on electronic health records. Journal of Comparative Effectiveness Research, 2021, 10,<br>777-795.                                                                   | 1.4  | 3         |
| 189 | CDK 4/6 inhibitor induced lung injury: a case report and review of literature. Ecancermedicalscience, 2021, 15, 1245.                                                                                                                                                                | 1.1  | 4         |
| 190 | Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy. Nature Cancer, 2021, 2, 658-671.                                                                              | 13.2 | 34        |

| #   | Article                                                                                                                                                                                                                                             | IF  | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 191 | Drug induced vitiligoâ€like depigmentation from a CDK 4/6 inhibitor. Asia-Pacific Journal of Clinical<br>Oncology, 2022, 18, .                                                                                                                      | 1.1 | 9         |
| 192 | Incidence and Severity of Myelosuppression With Palbociclib After Palliative Bone Radiation in<br>Advanced Breast Cancer: A Single Center Experience and Review of Literature. Clinical Breast Cancer,<br>2022, 22, e65-e73.                        | 2.4 | 10        |
| 193 | Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer. Frontiers in Oncology, 2021, 11, 693104.                                                                                                                              | 2.8 | 67        |
| 194 | CDK4/6 inhibitor-induced colitis: a case report and review of the literature. BMJ Case Reports, 2021, 14, e242766.                                                                                                                                  | 0.5 | 2         |
| 195 | Landmark trials in the medical oncology management of metastatic breast cancer. Seminars in Oncology, 2021, 48, 246-258.                                                                                                                            | 2.2 | 4         |
| 196 | Precision medicine in breast cancer: From clinical trials to clinical practice. Cancer Treatment<br>Reviews, 2021, 98, 102223.                                                                                                                      | 7.7 | 34        |
| 197 | Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth<br>Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update. Journal of Clinical<br>Oncology, 2021, 39, 3959-3977.                 | 1.6 | 121       |
| 198 | Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer. Cancers, 2021, 13, 3517.                                                                                                                                                                | 3.7 | 68        |
| 199 | Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor<br>2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2<br>trial. Breast Cancer Research, 2021, 23, 87. | 5.0 | 21        |
| 200 | Endocrine Therapy With or Without CDK4/6 Inhibitors in Women With Hormone-receptor Positive<br>Breast Cancer: What do we Know About the Effects on Cognition?. Clinical Breast Cancer, 2022, 22,<br>191-199.                                        | 2.4 | 8         |
| 201 | MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment. Cancers, 2021, 13, 4114.                                                                                                                                               | 3.7 | 10        |
| 202 | Hormonoterapia en cÃ;ncer de mama metastÃ;sico. Revisión de la Evidencia y Abordaje Terapéutico en el<br>Instituto Nacional de CancerologÃa, BogotÃ; - Colombia. Revista Colombiana De CancerologÃa, 0, 25,<br>142-151.                             | 0.2 | 0         |
| 203 | Breast Cancer Treatments: Updates and New Challenges. Journal of Personalized Medicine, 2021, 11, 808.                                                                                                                                              | 2.5 | 108       |
| 204 | Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials. Clinical and Translational Oncology, 2022, 24, 161-192.                                                                                                      | 2.4 | 31        |
| 205 | The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients. Anti-Cancer Drugs, 2022, 33, e628-e634.                                                                                             | 1.4 | 4         |
| 206 | Optimizing treatment selection, and sequencing decisions for Management of HR-Positive,<br>HER2-Negative advanced breast cancer – Proceedings from breast cancer expert group meeting. BMC<br>Proceedings, 2021, 15, 15.                            | 1.6 | 5         |
| 207 | The Effects of HER2 on CDK4/6 Activity in Breast Cancer. Clinical Breast Cancer, 2022, 22, e278-e285.                                                                                                                                               | 2.4 | 8         |
| 208 | The role of CDK4/6 inhibitors in early breast cancer. Breast, 2021, 58, 160-169.                                                                                                                                                                    | 2.2 | 18        |

| #   | Article                                                                                                                                                                                                                                                    | IF  | CITATIONS |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 209 | The efficacy and safety of palbociclib combined with endocrine therapy in patients with hormone receptor-positive HER2-negative advanced breast cancer: a multi-center retrospective analysis. Anti-Cancer Drugs, 2022, 33, e635-e643.                     | 1.4 | 4         |
| 210 | Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus<br>letrozole as first-line therapy for advanced breast cancer in an expanded population. Breast Cancer<br>Research and Treatment, 2021, 189, 689-699.    | 2.5 | 21        |
| 211 | Genomic Profiling of Premenopausal HR+ and HER2– Metastatic Breast Cancer by Circulating Tumor<br>DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and<br>Ribociclib. JCO Precision Oncology, 2021, 5, 1408-1420. | 3.0 | 15        |
| 212 | Efficacy of Fulvestrant in Women with Hormone-Resistant Metastatic Breast Cancer (mBC): A Canadian<br>Province Experience. Cancers, 2021, 13, 4163.                                                                                                        | 3.7 | 3         |
| 213 | Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in<br>Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen<br>Receptor Modulators. JAMA Oncology, 2021, 7, e213428.         | 7.1 | 18        |
| 214 | Real-world clinical profile, treatment patterns and patient-reported outcomes in a subset of<br>HR+/HER2- advanced breast cancer patients withÂpoor prognostic factors: data from an international<br>study. ESMO Open, 2021, 6, 100226.                   | 4.5 | 3         |
| 215 | The evolution of cyclin dependent kinase inhibitors in the treatment of cancer. Expert Review of Anticancer Therapy, 2021, 21, 1105-1124.                                                                                                                  | 2.4 | 26        |
| 216 | A practical guide to endocrine therapy in the management of estrogen receptor-positive male breast cancer Management, 2021, 10, BMT59.                                                                                                                     | 0.2 | 2         |
| 217 | From clinical trials to clinical practice: the use of everolimus and exemestane in the treatment of<br>hormone receptor-positive metastatic breast cancer: real-world data. Journal of Chemotherapy, 2021, ,<br>1-6.                                       | 1.5 | 0         |
| 218 | 6th Molecular Oncology Society Conference: Improving patient survival by molecularly targeted therapies. International Journal of Molecular and Immuno Oncology, 0, 6, 111-117.                                                                            | 0.0 | 0         |
| 220 | Combined endocrine and targeted therapy in luminal breast cancer. Expert Review of Anticancer<br>Therapy, 2021, 21, 1237-1251.                                                                                                                             | 2.4 | 12        |
| 221 | Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials. Breast, 2021, 59, 165-175.                                                                    | 2.2 | 8         |
| 222 | The effects of anticancer therapies on bone metastases in breast cancer. , 2022, , 987-1002.                                                                                                                                                               |     | 0         |
| 223 | Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review. Cancers, 2021, 13, 465.                                                                                                                                              | 3.7 | 7         |
| 224 | Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone<br>receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network<br>meta-analysis. Current Problems in Cancer, 2020, 44, 100606. | 2.0 | 11        |
| 225 | Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. Oncolmmunology, 2020, 9, 1710052.                                                                | 4.6 | 17        |
| 226 | Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane<br>in Postmenopausal Women with HR+, HER2â~ Advanced Breast Cancer. Clinical Cancer Research, 2020,<br>26, 6417-6428.                                 | 7.0 | 11        |
| 227 | Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer. Endocrine-Related Cancer, 2019, 26, R15-R30                                                                                                                                           | 3.1 | 96        |

| #   | Article                                                                                                                                                                                                                                                                 | IF   | CITATIONS |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 228 | CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2<br>(HER2)-negative metastatic breast cancer: Are we at the finish line?. Oncotarget, 2018, 9, 34193-34195.                                                                     | 1.8  | 2         |
| 229 | New drug: Ribociclib for breast cancer. Australian Prescriber, 2018, 41, 172.                                                                                                                                                                                           | 1.0  | 4         |
| 230 | Ribociclib for the treatment of hormone-positive HER2-negative breast cancer. Meditsinskiy Sovet, 2019, , 72-80.                                                                                                                                                        | 0.5  | 3         |
| 231 | The Pharmacological Profile of Cyclin-dependent Kinase (CDK) 4/6 Inhibitors: Clinical Management of<br>Toxicity and Drug Interactions Related to CDK 4/6 Inhibitor-based Treatment in Advanced/Metastatic<br>Breast Cancer. Forum of Clinical Oncology, 2019, 10, 2-14. | 0.2  | 3         |
| 232 | Hormonal therapy in premenopausal patients with SR-positive, HER2-negative breast cancer. Onkologie<br>(Czech Republic), 2019, 13, 24-28.                                                                                                                               | 0.1  | 1         |
| 233 | HORMONE-POSITIVE HER2-NEGATIVE METASTATIC BREAST CANCER: DECISION MAKING IN REAL CLINICAL PRACTICE. South Russian Journal of Cancer, 2020, 1, 46-51.                                                                                                                    | 0.6  | 8         |
| 234 | Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National<br>Comprehensive Cancer Network: JNCCN, 2020, 18, 452-478.                                                                                                        | 4.9  | 848       |
| 235 | A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor<br>receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors. Drugs in Context,<br>2018, 7, 1-6.                                                | 2.2  | 8         |
| 236 | The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC. Clinical Breast Cancer, 2022, 22, 223-234.                                                                                                               | 2.4  | 2         |
| 237 | Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone<br>Receptor–Positive, <i>ERBB2</i> -Negative Advanced Breast Cancer. JAMA Oncology, 2021, 7, 1791.                                                                 | 7.1  | 56        |
| 238 | Analyzing the scaffold diversity of cyclinâ€dependent kinase inhibitors and revisiting the clinical and preclinical pipeline. Medicinal Research Reviews, 2022, 42, 654-709.                                                                                            | 10.5 | 21        |
| 239 | Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone<br>receptor-positive HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment, 2022,<br>191, 191-207.                                                      | 2.5  | 0         |
| 240 | Drug-induced pulmonary toxicity in breast cancer patients treated with systemic therapy: a systematic literature review. Expert Review of Anticancer Therapy, 2021, 21, 1399-1410.                                                                                      | 2.4  | 0         |
| 241 | Type 1 Nuclear Receptor Activity in Breast Cancer: Translating Preclinical Insights to the Clinic.<br>Cancers, 2021, 13, 4972.                                                                                                                                          | 3.7  | 9         |
| 242 | Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2â^'<br>Breast Cancer. Clinical Cancer Research, 2022, 28, 163-174.                                                                                                         | 7.0  | 8         |
| 243 | Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials. Cancers, 2021, 13, 5198.                                                                                                                                                                       | 3.7  | 10        |
| 244 | Safety of cyclin-dependent kinase4/6 inhibitor combined with palliative radiotherapy in patients with metastatic breast cancer. Breast, 2021, 60, 163-167.                                                                                                              | 2.2  | 17        |
| 245 | PHARMACOECONOMIC EVALUATION OF RIBOCICLIB FOR THE FIRST-LINE TREATMENT OF HR-POSITIVE<br>HER2-NEGATIVE ADVANCED BREAST CANCER. Opuholi Zenskoj Reproduktivnoj Sistemy, 2018, 14, 21-35.                                                                                 | 0.4  | 2         |

| #<br>246 | ARTICLE<br>Endocrine Therapy of Metastatic Breast Cancer. , 2019, , 533-555.                                                                                                                                                                 | IF  | CITATIONS<br>0 |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----------------|
| 247      | Systemic Treatment Drugs and Regimens. , 2019, , 587-608.                                                                                                                                                                                    |     | 0              |
| 248      | Systemic Treatment Drugs/Regimens and Dose Modifications. , 2019, , 789-801.                                                                                                                                                                 |     | 0              |
| 249      | Breast Cancer in Older Women. , 2019, , 325-335.                                                                                                                                                                                             |     | 1              |
| 250      | Treatment of Metastatic Breast Cancer: Endocrine Therapy. , 2019, , 419-447.                                                                                                                                                                 |     | 0              |
| 251      | Cyclin-dependent kinase inhibitors: efficacy and safety. Meditsinskiy Sovet, 2019, , 42-55.                                                                                                                                                  | 0.5 | 2              |
| 252      | Neurological Complications of Targeted Therapies. , 2020, , 341-363.                                                                                                                                                                         |     | 0              |
| 253      | Protocole homéopathique d'accompagnement des inhibiteurs oraux des kinases dépendantes des<br>cyclines 4Âet 6 (CDK 4/6), dans le cancer du sein post-ménopausique métastatique hormonodépendant.<br>Revue D'Homeopathie, 2019, 10, 193-198.  | 0.1 | 0              |
| 255      | Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line<br>treatment of HR-positive HER2-negative advanced breast cancer. Farmakoekonomika, 2020, 12, 279-290.                                       | 1.2 | 1              |
| 256      | Hormone Receptor–Positive, HER2-Negative Breast Cancer: Recent Advances and Best Practices. Journal of the Advanced Practitioner in Oncology, 2020, 11, 275-279.                                                                             | 0.4 | 0              |
| 258      | Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience. Journal of Modern Oncology, 2020, 22, 98-103. | 0.3 | 0              |
| 259      | Clinical aspects of the use of ribociclib. Meditsinskiy Sovet, 2020, , 44-56.                                                                                                                                                                | 0.5 | 0              |
| 260      | Abemaciclibâ—¼ for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2â^') metastatic breast cancer. Cancer Nursing Practice, 0, , .                                                   | 0.0 | 0              |
| 261      | Options for Endocrine-Refractory, Hormone Receptor–Positive Breast Cancer: Which Target and<br>When?. Journal of Clinical Oncology, 2021, 39, 3890-3896.                                                                                     | 1.6 | 0              |
| 262      | Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2â^' Advanced<br>Breast Cancer: Biomarkers and Potential Novel Treatment Strategies. Cancers, 2021, 13, 5397.                                            | 3.7 | 7              |
| 263      | U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review. Clinical Cancer Research, 2022, 28, 1072-1086.                                                                                                                                | 7.0 | 31             |
| 264      | Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor–positive, HER2-negative<br>Breast Cancer and Emerging Therapeutic Opportunities. Clinical Cancer Research, 2022, 28, 821-830.                                       | 7.0 | 26             |
| 265      | Inhibitors of cyclin-dependent kinases 4/6 for breast cancer patients with different somatic mutations of the PIK3CA gene. Meditsinskiy Sovet, 2020, , 40-46.                                                                                | 0.5 | 1              |

| #   | Article                                                                                                                                                                                                                                                                        | IF  | CITATIONS |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 266 | Management of Advanced Breast Cancer in Young Women: What's New in Systemic Treatment. , 2020, ,<br>127-142.                                                                                                                                                                   |     | 0         |
| 267 | Potential aromatase inhibitors and antiestrogen agents based on stilbene and stilbazole derivatives.<br>Proceedings of the National Academy of Sciences of Belarus, Chemical Series, 2020, 56, 81-87.                                                                          | 0.1 | 0         |
| 268 | A Comparative Study on the Clinical Efficacy and Safety between Combination Therapy with CDK 4/6<br>Inhibitor and AI Versus AI Monotherapy in HR+/HER type2- Advanced Breast Cancer: Updated<br>Meta-analysis. Korean Journal of Clinical Pharmacy, 2020, 30, 1-10.            | 0.3 | 0         |
| 269 | Post-neoadjuvant treatment of breast cancer. Meditsinskiy Sovet, 2020, , 232-241.                                                                                                                                                                                              | 0.5 | 0         |
| 270 | ESR1 mutation as potential predictive marker for choice of treatment tactics in hormone-resistant<br>HR+/HER2-negative breast cancer. Medical Alphabet, 2020, , 68-73.                                                                                                         | 0.2 | 1         |
| 271 | A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach. American Journal of Cancer Research, 2018, 8, 2359-2376.                | 1.4 | 24        |
| 272 | Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement. Cancers, 2021, 13, 5643.                                                                                                                                 | 3.7 | 16        |
| 273 | Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer. Journal of Modern Oncology, 2021, 23, 470-476.                                                                                                                           | 0.3 | 0         |
| 274 | A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of<br>Patients with Advanced Hormone Receptor–positive Breast Cancer, SWOG S1222. Clinical Cancer<br>Research, 2022, 28, 611-617.                                                  | 7.0 | 4         |
| 275 | Baseline lymphopenia as prognostic factor in patients with metastatic breast cancer treated with palbociclib. Oncology Letters, 2021, 23, 25.                                                                                                                                  | 1.8 | 10        |
| 276 | Genomic characterization of de novo metastatic breast cancer. Clinical Breast Cancer, 2021, , .                                                                                                                                                                                | 2.4 | 1         |
| 277 | Systematic review and meta-analysis of post-progression outcomes in ER+/HER2â^' metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials. ESMO Open, 2021, 6, 100332.                                                                                | 4.5 | 16        |
| 278 | Risk of venous and arterial thromboembolic events in women with advanced breast cancer treated with CDK 4/6 inhibitors: A systematic review and meta-analysis. Thrombosis Research, 2021, 208, 190-197.                                                                        | 1.7 | 9         |
| 279 | Adjuvant abemaciclib for high-risk breast cancer: the story continues. Annals of Oncology, 2021, 32, 1457-1459.                                                                                                                                                                | 1.2 | 2         |
| 280 | Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2â^') breast cancer: a systematic review. Annals of Translational Medicine, 2022, 10, 233-233. | 1.7 | 5         |
| 281 | Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen<br>Receptor–Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor.<br>Clinical Cancer Research, 2022, 28, 1107-1116.                                                      | 7.0 | 7         |
| 282 | Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2– patients with metastatic breast cancer. Medicine (United States), 2021, 100, e27710.                                                                                               | 1.0 | 2         |
| 283 | Lineage-specific silencing of PSAT1 induces serine auxotrophy and sensitivity to dietary serine starvation in luminal breast tumors. Cell Reports, 2022, 38, 110278.                                                                                                           | 6.4 | 14        |

| #   | Article                                                                                                                                                                                                                                                                                                            | IF   | CITATIONS |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 284 | PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers. Cancers, 2022, 14, 599.                                                                                                                                                                                                 | 3.7  | 8         |
| 285 | Patient preferences for breast cancer treatments: a discrete choice experiment in France, Ireland,<br>Poland and Spain. Future Oncology, 2022, 18, 1115-1132.                                                                                                                                                      | 2.4  | 8         |
| 286 | Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone<br>receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER). European Journal of<br>Cancer, 2022, 161, 26-37.                                                                                  | 2.8  | 11        |
| 287 | Thrombotic events in patients using cyclin dependent kinase 4/6 inhibitors, analysis of existing ambulatory risk assessment models and the potential influences of tumor specific risk factors. Current Problems in Cancer, 2022, 46, 100832.                                                                      | 2.0  | 2         |
| 288 | Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer. JCO Precision Oncology, 2022, 6, e2100002.                                                                                                                                                    | 3.0  | 36        |
| 289 | Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of<br>Novel Therapies: A Guideline Appraisal. Journal of the National Comprehensive Cancer Network: JNCCN,<br>2022, 20, 37-44.                                                                                         | 4.9  | 7         |
| 291 | Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer.<br>Clinical and Translational Oncology, 2022, 24, 1033-1046.                                                                                                                                                 | 2.4  | 5         |
| 292 | Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response. , 2022, 236, 108108.                                                                                                                    |      | 25        |
| 293 | Palbociclib plus endocrine therapy significantly enhances overall survival of<br><scp>HR</scp> +/ <scp>HER2</scp> â^` metastatic breast cancer patients compared to endocrine therapy<br>alone in the secondâ€line setting: A large institutional study. International Journal of Cancer, 2022, 150,<br>2025-2037. | 5.1  | 16        |
| 294 | CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer. Future Oncology, 2022, 18, 1143-1157.                                                                                                                                                                     | 2.4  | 8         |
| 295 | The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone<br>Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature.<br>Frontiers in Oncology, 2022, 12, 797157.                                                                     | 2.8  | 1         |
| 296 | Ribociclib-associated organising pneumonia. BMJ Case Reports, 2021, 14, e245187.                                                                                                                                                                                                                                   | 0.5  | 1         |
| 297 | AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus<br>palbociclib <i>versus</i> letrozole plus palbociclib for previously untreated ER+/HER2– advanced<br>breast cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210839.                                                 | 3.2  | 16        |
| 298 | PALVEN: phase Ib trial of palbociclib, letrozole and venetoclax in estrogen receptor- and BCL2-positive advanced breast cancer. Future Oncology, 2022, 18, 1805-1816.                                                                                                                                              | 2.4  | 10        |
| 299 | Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth<br>factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1<br>trial. Breast Cancer Research and Treatment, 2022, 193, 95-103.                                       | 2.5  | 8         |
| 300 | Ribociclib efficacy in special populations and analysis of patient-reported outcomes in the MONALEESA trials. Expert Review of Anticancer Therapy, 2022, 22, 343-351.                                                                                                                                              | 2.4  | 6         |
| 301 | Ultrasonic Omics Based on Intelligent Classification Algorithm in Hormone Receptor Expression and Efficacy Evaluation of Breast Cancer. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-8.                                                                                                       | 1.3  | 2         |
| 302 | Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. New England Journal of<br>Medicine, 2022, 386, 942-950.                                                                                                                                                                                 | 27.0 | 220       |

| #   | Article                                                                                                                                                                                                                                                        | IF   | CITATIONS |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 303 | Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast<br>Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data. Cancer<br>Management and Research, 2022, Volume 14, 1033-1041. | 1.9  | 8         |
| 304 | 2021 Update on Systemic Therapy for Breast Cancer. Healthbook TIMES Oncology Hematology, 2022, , .                                                                                                                                                             | 0.1  | 0         |
| 305 | How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story. Life, 2022, 12, 378.                                                                                                                                    | 2.4  | 8         |
| 306 | Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67?. Lancet<br>Oncology, The, 2022, 23, 325-328.                                                                                                                         | 10.7 | 1         |
| 307 | A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis. Npj Breast<br>Cancer, 2022, 8, 35.                                                                                                                                 | 5.2  | 7         |
| 308 | 18F-FDG PET/CT Metabolic Response With Hormone Receptor–Positive, Human Epidermal Growth Factor<br>Receptor 2–Negative Breast Cancer Treated With Cyclin-Dependent 4/6 Kinase Inhibitors. Clinical<br>Nuclear Medicine, 0, Publish Ahead of Print, .           | 1.3  | 4         |
| 309 | Ribociclib-Induced Pseudo-Acute Kidney Injury. Journal of Onco-Nephrology, 0, , 239936932210852.                                                                                                                                                               | 0.6  | 4         |
| 310 | Association between age at initial diagnosis and post-metastasis mortality among women with recurrent metastatic breast cancer in China. BMC Cancer, 2022, 22, 385.                                                                                            | 2.6  | 10        |
| 311 | Neuroendocrine Neoplasms of the Breast: The Latest WHO Classification and Review of the Literature.<br>Cancers, 2022, 14, 196.                                                                                                                                 | 3.7  | 4         |
| 312 | Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer. Breast, 2022, 62, S70-S79.                                                                                                                                                | 2.2  | 10        |
| 313 | Clinical case of the treatment of metastatic luminal breast cancer. Meditsinskiy Sovet, 2021, , 160-166.                                                                                                                                                       | 0.5  | 0         |
| 314 | Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast<br>Cancer: Overview of Clinical Data and Patients Selection. Breast Cancer: Targets and Therapy, 2022,<br>Volume 14, 101-111.                                 | 1.8  | 2         |
| 315 | Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal<br>patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.<br>European Journal of Cancer, 2022, 168, 12-24.         | 2.8  | 9         |
| 316 | Functional Genomic Analysis of <i>CDK4</i> and <i>CDK6</i> Gene Dependency across Human Cancer<br>Cell Lines. Cancer Research, 2022, 82, 2171-2184.                                                                                                            | 0.9  | 12        |
| 318 | Cancer as a new chronic disease: Oncology nursing in the 21st Century Canadian Oncology Nursing<br>Journal = Revue Canadienne De Nursing Oncologique, 2022, 32, 87-92.                                                                                         | 0.5  | 0         |
| 319 | Real world incidence and management of adverse events in patients with HR+, HER2â^ metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting. Current Medical Research and Opinion, 2022, 38, 1319-1331.                   | 1.9  | 9         |
| 320 | Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study. BMC Cancer, 2022, 22, 516.                                                                                  | 2.6  | 11        |
| 321 | Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial. Radiology and Oncology, 2022, 56, 238-247.         | 1.7  | 3         |

| #   | Article                                                                                                                                                                                                                                                                     | IF  | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 323 | VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast<br>Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results. Clinical Cancer Research,<br>2022, 28, 3256-3267.                                            | 7.0 | 28        |
| 324 | Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer. Annals of Oncology, 2022, 33, 769-785.                                                                                                                             | 1.2 | 37        |
| 325 | Changes in Body Adiposity in Women Undergoing Breast Cancer Treatment: A Scoping Review.<br>Nutrition and Cancer, 0, , 1-15.                                                                                                                                                | 2.0 | 1         |
| 326 | NCCN Guidelines Updates: Management of Patients With HER2-Negative Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 561-565.                                                                                                           | 4.9 | 4         |
| 327 | Role of CDK4/6 inhibitors in patients with hormone receptor (HR)-positive, human epidermal receptor-2 negative (HER-2) metastatic breast cancer study protocol for a systematic review, network meta-analysis and cost-effectiveness analysis. BMJ Open, 2022, 12, e056374. | 1.9 | 3         |
| 329 | Cost-effectiveness of ribociclib for premenopausal or perimenopausal women with HR+/HER2â^'<br>advanced breast cancer: a Brazilian public health care system perspective. Therapeutic Advances in<br>Medical Oncology, 2022, 14, 175883592211008.                           | 3.2 | 0         |
| 330 | Exploring new pathways in endocrine-resistant breast cancer. Exploration of Targeted Anti-tumor Therapy, 0, , 337-361.                                                                                                                                                      | 0.8 | 2         |
| 331 | Breast Cancer Epidemiology and Contemporary Breast Cancer Care: A Review of the Literature and Clinical Applications. Clinical Obstetrics and Gynecology, 2022, 65, 461-481.                                                                                                | 1.1 | 6         |
| 332 | Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk<br>breast cancer. Expert Review of Anticancer Therapy, 2022, 22, 805-814.                                                                                               | 2.4 | 2         |
| 333 | Arrhythmic Complications Associated with Cancer Therapies. Heart Failure Clinics, 2022, 18, 375-383.                                                                                                                                                                        | 2.1 | 2         |
| 334 | Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement<br>on Breast Cancer. Pathology and Oncology Research, 0, 28, .                                                                                                           | 1.9 | 12        |
| 335 | Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic<br>Breast Cancer: A Systematic Review. International Journal of Molecular Sciences, 2022, 23, 7079.                                                                    | 4.1 | 4         |
| 336 | Prediction for Distant Metastasis of Breast Cancer Using Dynamic Contrast-Enhanced Magnetic<br>Resonance Imaging Images under Deep Learning. Computational Intelligence and Neuroscience, 2022,<br>2022, 1-7.                                                               | 1.7 | 5         |
| 337 | Biomarkers for Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Hormone<br>Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced/Metastatic Breast<br>Cancer: Translation to Clinical Practice. JCO Precision Oncology, 2022, , .          | 3.0 | 4         |
| 339 | Cyclin-dependent kinase inhibition and its intersection with immunotherapy in breast cancer: more than CDK4/6 inhibition. Expert Opinion on Investigational Drugs, 2022, 31, 933-944.                                                                                       | 4.1 | 0         |
| 340 | Expression patterns and therapeutic implications of CDK4 across multiple carcinomas: a molecular docking and MD simulation study. , 2022, 39, .                                                                                                                             |     | 27        |
| 341 | Targeted Approaches to HER2-Low Breast Cancer: Current Practice and Future Directions. Cancers, 2022, 14, 3774.                                                                                                                                                             | 3.7 | 10        |
| 342 | Work productivity among patients with metastatic breast cancer in the United States. Expert Review of Pharmacoeconomics and Outcomes Research, 0, , 1-9.                                                                                                                    | 1.4 | 0         |

| #   | Article                                                                                                                                                                                                                                                             | IF   | CITATIONS |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 343 | Real world evidence study on treatment patterns and health resource utilization in patients with<br>HR+/HER2- locally advanced or metastatic breast cancer in Korea. Journal of Drug Assessment, 2022, 11,<br>12-19.                                                | 2.2  | 2         |
| 344 | Severe acute radiation dermatitis after palbociclib therapy in the setting of palliative radiotherapy.<br>Journal of Oncology Pharmacy Practice, 2023, 29, 764-767.                                                                                                 | 0.9  | 0         |
| 345 | HER2-low expression does not affect the clinical outcomes of metastatic breast cancer treated with CDK4/6 inhibitor: A real-world study. Frontiers in Endocrinology, 0, 13, .                                                                                       | 3.5  | 13        |
| 347 | Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer. JCI Insight, 2022, 7, .                                                                                                                                                                   | 5.0  | 6         |
| 348 | CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive,<br>HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28<br>randomized controlled trials. Frontiers in Oncology, 0, 12, . | 2.8  | 3         |
| 349 | Targeted therapy for breast cancer: An overview of drug classes and outcomes. Biochemical<br>Pharmacology, 2022, 204, 115209.                                                                                                                                       | 4.4  | 38        |
| 350 | Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2â^' Breast<br>Cancer Based on a Window of Opportunity Study. Current Issues in Molecular Biology, 2022, 44,<br>4255-4267.                                                      | 2.4  | 0         |
| 351 | Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi<br>approach. Frontiers in Oncology, 0, 12, .                                                                                                                     | 2.8  | 0         |
| 352 | Time to Chemotherapy for Patients With Estrogen Receptor-Positive Breast Cancer and<br>Cyclin-Dependent Kinase 4 and 6 Inhibitor Use. Journal of Breast Cancer, 2022, 25, 296.                                                                                      | 1.9  | 1         |
| 353 | CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review). International Journal of<br>Molecular Medicine, 2022, 50, .                                                                                                                               | 4.0  | 15        |
| 354 | Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2â^' Advanced<br>Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study. Targeted<br>Oncology, 0, , .                                       | 3.6  | 1         |
| 355 | Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+,<br>HER2â" Metastatic Breast Cancer Treated with Abemaciclib. Drugs - Real World Outcomes, 2022, 9,<br>681-693.                                                      | 1.6  | 4         |
| 356 | Arthralgia induced by endocrine therapy with or without cyclinâ€dependent kinase 4/6 inhibitors in<br>breast cancer: A systematic review and metaâ€analysis. Asia-Pacific Journal of Clinical Oncology, 0, , .                                                      | 1.1  | 0         |
| 357 | Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer. Npj Precision Oncology, 2022, 6, .                                                                                                                       | 5.4  | 10        |
| 358 | Mechanisms of Resistance to CDK4/6 Inhibitors in Hormone Receptor-Positive (HR +) Breast Cancer:<br>Spotlight on Convergent CDK6 Upregulation and Immune Signaling. Current Breast Cancer Reports, 0,<br>, .                                                        | 1.0  | 0         |
| 359 | Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and<br>Current Status. Drug Design, Development and Therapy, 0, Volume 16, 2933-2948.                                                                                    | 4.3  | 21        |
| 360 | Emerging Targeted Therapies for Early Breast Cancer. Drugs, 2022, 82, 1437-1451.                                                                                                                                                                                    | 10.9 | 5         |
| 361 | Absolute Lymphocyte Count Is an Independent Prognostic Factor for ER-positive HER2-negative Advanced Breast Cancer Patients Treated With CDK4/6 Inhibitors. Anticancer Research, 2022, 42,                                                                          | 1.1  | 2         |

| щ   |                                                                                                                                                                                                                                                                             | IE  | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| #   | ARTICLE                                                                                                                                                                                                                                                                     | IF  | CITATIONS |
| 362 | cancer: A multicenter study. Breast, 2022, 66, 85-88.                                                                                                                                                                                                                       | 2.2 | 4         |
| 363 | Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer:<br>Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial. Breast, 2022, 66, 77-84.                                                               | 2.2 | 3         |
| 364 | A Hormone Immunotherapy (HIT) Combination in Advanced Breast Cancer. , 2022, , .                                                                                                                                                                                            |     | 0         |
| 366 | A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors. Cancers, 2022, 14, 4996.                                                                                                                  | 3.7 | 0         |
| 367 | Ribociclib Plus Letrozole in Italian Male Patients with Hormone Receptor–Positive, Human Epidermal<br>Growth Factor Receptor 2–Negative Advanced Breast Cancer: Case Studies of Phase 3b CompLEEment-1<br>Trial. Breast Cancer: Targets and Therapy, 0, Volume 14, 351-362. | 1.8 | 0         |
| 368 | Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with<br>HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized<br>PARSIFAL Trial. Oncologist, 2023, 28, 23-32.                                            | 3.7 | 6         |
| 369 | Small molecule inhibitors targeting the cancers. MedComm, 2022, 3, .                                                                                                                                                                                                        | 7.2 | 25        |
| 370 | Clinical Characteristics and Survival Outcomes of Patients with De Novo Metastatic Breast Cancer.<br>Breast Cancer: Targets and Therapy, 0, Volume 14, 363-373.                                                                                                             | 1.8 | 3         |
| 371 | ESR1 activating mutations: From structure to clinical application. Biochimica Et Biophysica Acta:<br>Reviews on Cancer, 2023, 1878, 188830.                                                                                                                                 | 7.4 | 10        |
| 372 | Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib. Breast, 2022, 66, 157-161.                                                                               | 2.2 | 4         |
| 373 | The Combination of CDK 4/6 Inhibitors plus Endocrine Treatment versus Endocrine Treatment Alone in<br>Hormone-receptor (HR)-Positive breast Cancer: a Systematic Review and Meta-analysis. Medicinski Arhiv<br>= Medical Archives = Archives De Médecine, 2022, 76, 333.    | 0.9 | 1         |
| 374 | The Clinical Utility of ESR1 Mutations in Hormone Receptor-Positive, HER2-Negative Advanced Breast<br>Cancer. Hematology/Oncology Clinics of North America, 2023, 37, 169-181.                                                                                              | 2.2 | 3         |
| 375 | Antitumor response and quality of life: is there a need to sacrifice? Clinical observation: long-term and safe control of the disease using a combination of ribociclib with letrozole. Case report. Journal of Modern Oncology, 2022, 24, 373-379.                         | 0.3 | 0         |
| 376 | Effect of ribociclib on productivity losses due to breast cancer in young women in Brazil. Revista De<br>Saude Publica, 0, 56, 100.                                                                                                                                         | 1.7 | 0         |
| 377 | Incidence of and risk factors for non-hematologic toxicity with combined radiotherapy and CDK4/6 inhibitors in metastatic breast cancer using dose-volume parameters analysis: a multicenter cohort study. Breast Cancer, 2023, 30, 282-292.                                | 2.9 | 3         |
| 378 | Case report: 18F-FES PET/CT predicted treatment responses of second-line and third-line CDK4/6 inhibitors after disease progression on first-line CDK4/6 inhibitor in a HR+/HER2- metastatic breast cancer patient. Frontiers in Oncology, 0, 12, .                         | 2.8 | 1         |
| 379 | Endocrine Therapy-Based Strategies for Metastatic Breast Cancer with Different Endocrine Sensitivity Statuses: A Systematic Review and Network Meta-Analysis. Cancers, 2022, 14, 6100.                                                                                      | 3.7 | 4         |
| 380 | CDK4/6 Inhibitors as Upfront Treatment in a Patient with Breast Cancer Presenting with a Clinical Critic Situation: A Case Report and Review of the Literature. Current Oncology, 2022, 29, 9630-9639.                                                                      | 2.2 | 0         |

| ~     |    | _      |    |
|-------|----|--------|----|
|       | ON | 12 FD( | DT |
| CITAT |    | NLFV   |    |

| #   | Article                                                                                                                                                                                                                                                                                                  | IF  | CITATIONS |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 381 | Therapeutic drug monitoring in breast cancer therapy – LC-MS/MS method for quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, ribociclib, and major metabolites abemaciclib M20 and M2 in human serum. Journal of Pharmaceutical and Biomedical Analysis, 2023, 225, 115211.              | 2.8 | 8         |
| 382 | Real-world effectiveness of ribociclib in metastatic breast cancer patients: Does dose affect survival?.<br>Journal of Oncology Pharmacy Practice, 2023, 29, 1619-1627.                                                                                                                                  | 0.9 | 2         |
| 383 | Role of ribociclib in treatment of luminal Her-2-negative mBC with CNS metastases. Meditsinskiy Sovet, 2022, , 42-51.                                                                                                                                                                                    | 0.5 | 0         |
| 385 | How I treat HER2-low advanced breast cancer. Breast, 2023, 67, 116-123.                                                                                                                                                                                                                                  | 2.2 | 5         |
| 386 | Hormone receptor-positive, HER2-negative, metastatic breast cancer responded well to abemaciclib<br>and exemestane after palbociclib and fulvestrant failure: A case report and literature review.<br>Frontiers in Oncology, 0, 12, .                                                                    | 2.8 | 1         |
| 387 | Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study. Cancers, 2023, 15, 316.                                                                                                                                 | 3.7 | 3         |
| 388 | A rapid reduction in tumor size by cyclin-dependent kinase inhibition in hormone receptor-positive postpartum breast cancer: a case report of two patients and a review of the literature. Annals of Translational Medicine, 2022, 10, 1413-1413.                                                        | 1.7 | 0         |
| 389 | Safety and Feasibility of Radiation Therapy Combined with CDK 4/6 Inhibitors in the Management of Advanced Breast Cancer. Cancers, 2023, 15, 690.                                                                                                                                                        | 3.7 | 5         |
| 390 | The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer. Expert Review of Anticancer Therapy, 0, , 1-8.                                                                                                                                                | 2.4 | 0         |
| 391 | Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors. Frontiers in Oncology, 0, 12, .                                                                                                                        | 2.8 | 2         |
| 392 | Development and Validation of a Quantitative LC-MS/MS Method for CDK4/6 Inhibitors Palbociclib,<br>Ribociclib, Abemaciclib, and Abemaciclib-M2 in Human Plasma. Therapeutic Drug Monitoring, 2023, 45,<br>327-336.                                                                                       | 2.0 | 6         |
| 394 | CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone<br>Receptor-Positive Breast Cancer. Cancers, 2023, 15, 1763.                                                                                                                                                  | 3.7 | 4         |
| 395 | Clinicopathological features and prognosis of breast cancer combined with symptomatic bone<br>marrow metastases: A 10â€year, singleâ€center, realâ€world study of 67 cases. Cancer Medicine, 0, , .                                                                                                      | 2.8 | 2         |
| 396 | The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis. EClinicalMedicine, 2023, 56, 101824.                                           | 7.1 | 1         |
| 397 | Shifting Treatment Paradigms: Improvements in HR-Positive, HER-2- Negative Breast Cancer Care in Poland from a Clinical Perspective. Biomedicines, 2023, 11, 510.                                                                                                                                        | 3.2 | 0         |
| 398 | Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands. JAMA Network Open, 2023, 6, e2256170.                                                                                                                     | 5.9 | 0         |
| 399 | Justifying Ribociclib Dose in Patients with Advanced Breast Cancer with Renal Impairment Based on PK,<br>Safety, and Efficacy Data: An Innovative Approach Integrating Data from a Dedicated Renal Impairment<br>Study and Oncology Clinical Trials. Clinical Pharmacokinetics, 2023, 62, 493-504.       | 3.5 | 4         |
| 400 | Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2â^' advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2. Journal of Medical Economics, 2023, 26, 357-365. | 2.1 | 3         |

| #   | Article                                                                                                                                                                                                       | IF    | CITATIONS |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-----------|
| 401 | Advances in medical treatment of breast cancer in 2022. , 2023, 2, 1-17.                                                                                                                                      |       | 2         |
| 402 | Cardiotoxicity from neoadjuvant targeted treatment for breast cancer prior to surgery. Frontiers in<br>Cardiovascular Medicine, 0, 10, .                                                                      | 2.4   | 1         |
| 403 | Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer. International Journal of Molecular Sciences, 2023, 24, 4522.                                                                                         | 4.1   | 16        |
| 405 | Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in<br>HR+/HER2-Metastatic Breast Cancer—A Review of the Literature. Diagnostics, 2023, 13, 987.                           | 2.6   | 5         |
| 406 | HR+/HER2– de novo metastatic breast cancer: a true peculiar entity?. Drugs in Context, 0, 12, 1-19.                                                                                                           | 2.2   | 2         |
| 407 | Efficacy of CDK 4/6 Inhibitors and Radiotherapy in Breast Cancer Patients with Brain Metastases.<br>Journal of Clinical Medicine, 2023, 12, 2044.                                                             | 2.4   | 1         |
| 408 | Systematic review of the management of brain metastases from hormone receptor positive breast cancer. Journal of Neuro-Oncology, 2023, 162, 45-57.                                                            | 2.9   | 6         |
| 409 | Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with<br>Metastatic Breast Cancer?. Medicina (Lithuania), 2023, 59, 557.                                           | 2.0   | 1         |
| 410 | Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2â^' Metastatic Breast<br>Cancer in Postmenopausal Women in the USA. Pharmacoeconomics, 2023, 41, 709-718.                      | 3.3   | 6         |
| 411 | Novel therapeutics in low-grade serous ovarian cancer. International Journal of Gynecological Cancer, 2023, 33, 377-384.                                                                                      | 2.5   | 4         |
| 412 | Post-CDK 4/6 Inhibitor Therapy: Current Agents and Novel Targets. Cancers, 2023, 15, 1855.                                                                                                                    | 3.7   | 1         |
| 413 | Systemic therapy for hormone receptorâ€positive/human epidermal growth factor receptor 2â€negative<br>early stage and metastatic breast cancer. Ca-A Cancer Journal for Clinicians, 2023, 73, 480-515.        | 329.8 | 23        |
| 414 | CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective. Frontiers in Cell and Developmental Biology, 0, 11, .                                                            | 3.7   | 6         |
| 415 | Stromal Senescence following Treatment with the CDK4/6 Inhibitor Palbociclib Alters the Lung<br>Metastatic Niche and Increases Metastasis of Drug-Resistant Mammary Cancer Cells. Cancers, 2023, 15,<br>1908. | 3.7   | 5         |
| 416 | Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer. Cancers, 2023, 15, 2015.                                      | 3.7   | 3         |
| 417 | <scp>CDK4</scp> /6 inhibitor modulating active and quiescent intestinal stem cells for prevention of chemotherapyâ€induced diarrhea. Journal of Pathology, 0, , .                                             | 4.5   | 1         |
| 418 | Advances in Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer. Current Oncology Reports, 2023, 25, 689-698.                                                                              | 4.0   | 2         |
| 419 | Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review. Medicina (Lithuania), 2023, 59, 696.                                                          | 2.0   | 1         |

| #   | Article                                                                                                                                                                                                                                                                                                                         | IF   | CITATIONS |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 420 | A retrospective, non-interventional study of breast cancer patients diagnosed with ER+/HER2 negative,<br>locally advanced or metastatic breast cancer treated with palbociclib in Denmark. Acta Oncológica,<br>2023, 62, 290-297.                                                                                               | 1.8  | 0         |
| 421 | Second-line Endocrine Therapy of Hormone Receptor-Positive/HER2-negative Advanced Breast Cancer: A<br>Systematic Review and Network Meta-analysis. Current Cancer Drug Targets, 2023, 23, .                                                                                                                                     | 1.6  | 0         |
| 422 | Advances in pharmacotherapies that target the cell cycle for treatment of breast cancer: where are we at today?. Expert Opinion on Pharmacotherapy, 2023, 24, 887-900.                                                                                                                                                          | 1.8  | 2         |
| 423 | Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal<br>Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer. Patient Preference and<br>Adherence, 0, Volume 17, 1049-1062.                                                                                       | 1.8  | Ο         |
| 424 | Treatment Patterns and Health Resource Utilization in Patients With HR+/ HER2- Locally Advanced or<br>Metastatic Breast Cancer in a Real-World Setting in Taiwan. Value in Health Regional Issues, 2023, 36,<br>98-104.                                                                                                         | 1.2  | 0         |
| 425 | Characterization of clinicopathological features, treatment practices, and outcomes among Finnish advanced breast cancer patients in real-life clinical practice. Journal of Cancer Research and Clinical Oncology, 2023, 149, 9139-9149.                                                                                       | 2.5  | 1         |
| 427 | Targeting protein tyrosine phosphatases for CDK6-induced immunotherapy resistance. Cell Reports, 2023, 42, 112314.                                                                                                                                                                                                              | 6.4  | 0         |
| 429 | Toxic hepatitis in metastatic breast cancer patient using ribociclib and denosumab. Journal of Oncology Pharmacy Practice, 2023, 29, 1494-1497.                                                                                                                                                                                 | 0.9  | 1         |
| 430 | Clinical trial designs for evaluating and exploiting cancer evolution. Cancer Treatment Reviews, 2023, 118, 102583.                                                                                                                                                                                                             | 7.7  | 2         |
| 432 | Safety of CDK4/6 Inhibitors Combined with Radiotherapy in Patients with Metastatic Breast Cancer: A<br>Review of the Literature. Current Oncology, 2023, 30, 5485-5496.                                                                                                                                                         | 2.2  | 1         |
| 433 | The trichotomy of <scp>HER2</scp> expression confers new insights into the understanding and managing for breast cancer stratified by <scp>HER2</scp> status. International Journal of Cancer, 2023, 153, 1324-1336.                                                                                                            | 5.1  | 2         |
| 434 | Managing a Long and Winding Road: Estrogen Receptor–Positive Breast Cancer. American Society of<br>Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2023, , .                                                                                                                           | 3.8  | 1         |
| 435 | Cost-effectiveness of the addition of CDK4/6 inhibitors to standard endocrine therapy in first-line<br>treatment of women with advanced HR+/HER2â^' breast cancer in Mexico. Clinical and Translational<br>Oncology, 2024, 26, 239-244.                                                                                         | 2.4  | 1         |
| 436 | Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer. Breast Cancer Research and Treatment, 2023, 201, 377-385.                                                                                                   | 2.5  | 0         |
| 437 | CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2â^' Advanced or<br>Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis. Cancers,<br>2023, 15, 3386.                                                                                                   | 3.7  | 2         |
| 438 | Ribociclib-induced acute kidney injury in patients with advanced-stage breast cancer: A case series and literature review. Current Problems in Cancer Case Reports, 2023, 11, 100243.                                                                                                                                           | 0.1  | 0         |
| 439 | Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature. Frontiers in Oncology, 0, 13, .                                                                                                                                                         | 2.8  | 0         |
| 440 | Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology. The. 2023, 24, 646-657. | 10.7 | 11        |

| #   | Article                                                                                                                                                                                                                             | IF  | CITATIONS |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 441 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer. ESMO Open, 2023, 8, 101541.                                                                 | 4.5 | 4         |
| 442 | Regulation of the Cell Cycle by ncRNAs Affects the Efficiency of CDK4/6 Inhibition. International<br>Journal of Molecular Sciences, 2023, 24, 8939.                                                                                 | 4.1 | 2         |
| 443 | Effect of Concurrent Proton Pump Inhibitors With Palbociclib Tablets for Metastatic Breast Cancer.<br>Clinical Breast Cancer, 2023, , .                                                                                             | 2.4 | 1         |
| 444 | Treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy. International Journal of<br>Molecular Sciences, 2023, 24, 9571.                                                                                             | 4.1 | 4         |
| 445 | Search for predictors of the efficiency of treatment with CDK4/6 inhibitors with HR+/HER2 metastatic breast cancer. Onkologiya Zhurnal Imeni P A Gertsena, 2023, 12, 34.                                                            | 0.2 | 0         |
| 446 | Advancing oncology drug therapies for sub-Saharan Africa. PLOS Global Public Health, 2023, 3, e0001653.                                                                                                                             | 1.6 | 0         |
| 447 | Disproportionality Analysis of Abemaciclib inÂtheÂFDA Adverse Event Reporting System: AÂReal-World<br>Post-Marketing Pharmacovigilance Assessment. Drug Safety, 2023, 46, 881-895.                                                  | 3.2 | 2         |
| 449 | First-line treatment of hormone-sensitive metastatic breast cancer. , 2023, , .                                                                                                                                                     |     | 0         |
| 450 | Luminal breast cancer treatment beyond cell cycle inhibitors. , 2023, , .                                                                                                                                                           |     | 0         |
| 451 | Quantitative Assessment of Ribociclib Exposure–Response Relationship to Justify Dose Regimen in<br>Patients with Advanced Breast Cancer. Journal of Clinical Pharmacology, 2023, 63, 1359-1370.                                     | 2.0 | 2         |
| 452 | CDK4/6 Inhibitor Resistance in Hormone Receptor-Positive Metastatic Breast Cancer: Translational<br>Research, Clinical Trials, and Future Directions. International Journal of Molecular Sciences, 2023, 24,<br>11791.              | 4.1 | 2         |
| 453 | Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine<br>Therapy With or Without Palbociclib in the PALLAS Trial. Journal of Clinical Oncology, 2023, 41,<br>5118-5130.                  | 1.6 | 2         |
| 454 | Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer. Npj Breast Cancer, 2023, 9, .                                                                                          | 5.2 | 0         |
| 456 | Systematic review of time to subsequent therapy as a candidate surrogate endpoint in advanced solid tumors. Future Oncology, 2023, 19, 1627-1639.                                                                                   | 2.4 | 0         |
| 457 | Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine<br>therapies in HR+/HER-2 â^ metastatic or advanced breast cancer patients: a network meta-analysis. BMC<br>Cancer, 2023, 23, . | 2.6 | 1         |
| 458 | The Therapeutic Potential of CDK4/6 Inhibitors, Novel Cancer Drugs, in Kidney Diseases. International Journal of Molecular Sciences, 2023, 24, 13558.                                                                               | 4.1 | 0         |
| 459 | Hematological Events Potentially Associated with CDK4/6 Inhibitors: An Analysis from the European Spontaneous Adverse Event Reporting System. Pharmaceuticals, 2023, 16, 1340.                                                      | 3.8 | 0         |
| 460 | The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer.<br>Cancers, 2023, 15, 4835.                                                                                                          | 3.7 | 1         |

| #   | Article                                                                                                                                                                                                                                                                                                   | IF   | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 461 | Aggressiveness of Cancer Care at End of Life in Patients with Metastatic Breast Cancer in Jordan.<br>Journal of Multidisciplinary Healthcare, 0, Volume 16, 2873-2881.                                                                                                                                    | 2.7  | 0         |
| 462 | Efficacy and safety of cyclinâ€dependent kinase 4/6 inhibitor in patients with advanced breast cancer: A<br>realâ€world experience. Thoracic Cancer, 2023, 14, 3012-3019.                                                                                                                                 | 1.9  | 0         |
| 463 | The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition. Breast Cancer, 2023, 30, 872-884.                                                                                                                                                  | 2.9  | 1         |
| 464 | Sacituzumab Govitecan for the Treatment of HR+/HER2- Breast Cancer in Heavily Pre-treated Patients.<br>Touch Reviews in Oncology & Haematology, 2023, 19, 1.                                                                                                                                              | 0.2  | 0         |
| 465 | Analysis of the regional clinical use of CDK4/6 inhibitor ribociclib as a mechanism of integration of a research approach in drug provision. Meditsinskiy Sovet, 2023, , 119-131.                                                                                                                         | 0.5  | 0         |
| 466 | CDK4/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity – a narrative review. Therapeutic Advances in Medical Oncology, 2023, 15, .                                                                                                             | 3.2  | 3         |
| 467 | Oral selective estrogen receptor degraders (SERDs): The new emperors in breast cancer clinical practice?. Seminars in Oncology, 2023, 50, 90-101.                                                                                                                                                         | 2.2  | 0         |
| 468 | Genomic Alterations Associated with Estrogen Receptor Pathway Activity in Metastatic Breast Cancer<br>Have a Differential Impact on Downstream ER Signaling. Cancers, 2023, 15, 4416.                                                                                                                     | 3.7  | 0         |
| 469 | Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials. Annals of Oncology, 2023, 34, 1003-1014.                                                                                                                                                                                      | 1.2  | 4         |
| 470 | Updated Austrian treatment algorithm for metastatic triple-negative breast cancer. Wiener Klinische<br>Wochenschrift, 0, , .                                                                                                                                                                              | 1.9  | 0         |
| 471 | Corrected QT Interval (QTc) Diagnostic App for the Oncological Routine: Development Study. JMIR<br>Cardio, 0, 7, e48096.                                                                                                                                                                                  | 1.7  | 1         |
| 473 | Efficacy of adjuvant CDK4/6 inhibitors in hormone receptor-positive breast cancer: a systematic review and meta-analysis. Expert Opinion on Pharmacotherapy, 2023, 24, 1901-1909.                                                                                                                         | 1.8  | 0         |
| 474 | Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes<br>in Predominantly Older Patients with HR+/HER2â^ Metastatic Breast Cancer Receiving Abemaciclib in<br>Routine Clinical Practice. Drugs - Real World Outcomes, 0, , .                                  | 1.6  | 0         |
| 475 | Recent Developments in the Therapeutic Landscape of Advanced or Metastatic Hormone<br>Receptor–Positive Breast Cancer. Cancer Research and Treatment, 2023, 55, 1065-1076.                                                                                                                                | 3.0  | 1         |
| 476 | CDK4/6 inhibition in hormone receptor-positive/HER2-negative breast cancer: Biological and clinical aspects. Cytokine and Growth Factor Reviews, 2024, 75, 57-64.                                                                                                                                         | 7.2  | 1         |
| 477 | LncRNA EILA promotes CDK4/6 inhibitor resistance in breast cancer by stabilizing cyclin E1 protein.<br>Science Advances, 2023, 9, .                                                                                                                                                                       | 10.3 | 1         |
| 478 | A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer. Breast Cancer Research and Treatment, 0, , .                                                                                                                                                | 2.5  | 1         |
| 479 | Adequate effectiveness of ribociclib plus letrozole or fulvestrant in patients with advanced or<br>metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast<br>cancer treated in routine Bulgarian clinical practice. Biotechnology and Biotechnological Equipment, | 1.3  | 0         |

| #   | Article                                                                                                                                                                                                                                                                                                                                      | IF   | CITATIONS |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 480 | Clinical Impact of CDK4/6 Inhibitors in De Novo or PRâ^' or Very Elderly Post-Menopausal ER+/HER2â^'<br>Advanced Breast Cancers. Cancers, 2023, 15, 5164.                                                                                                                                                                                    | 3.7  | 0         |
| 481 | The Diversity of Liquid Biopsies and Their Potential in Breast Cancer Management. Cancers, 2023, 15, 5463.                                                                                                                                                                                                                                   | 3.7  | 1         |
| 482 | Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2â^' metastatic breast cancer?. Annals of Oncology, 2023, , .                                                                                                                                                                  | 1.2  | 0         |
| 483 | Simple and rapid quantification of ribociclib in rat plasma by protein precipitation and LCâ€MS/MS: An application to pharmacokinetics of ribociclib nanoparticles in rats. Journal of Mass Spectrometry, 2023, 58, .                                                                                                                        | 1.6  | 1         |
| 484 | Efficacy of cyclin-dependent kinase 4/6 inhibitors in combination with hormonal therapy in patients with recurrent granulosa cell tumor of the ovary: A case series. Gynecologic Oncology Reports, 2023, 50, 101297.                                                                                                                         | 0.6  | 0         |
| 485 | Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study. Breast Cancer Research and Treatment, 0, , .                                                                                                                                                                          | 2.5  | 0         |
| 486 | Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic Approaches.<br>International Journal of Molecular Sciences, 2023, 24, 16198.                                                                                                                                                                                   | 4.1  | 1         |
| 487 | Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy. Cancers, 2023, 15, 5499.                                                                                                                                                                                                               | 3.7  | 0         |
| 488 | Genetic Testing Enhances the Precision Diagnosis and Treatment of Breast Cancer. International<br>Journal of Molecular Sciences, 2023, 24, 16607.                                                                                                                                                                                            | 4.1  | 2         |
| 489 | Polypharmacy and drug-drug interactions in metastatic breast cancer patients receiving cyclin-dependent kinase (CDK) 4/6 inhibitors. Journal of Oncology Pharmacy Practice, 0, , .                                                                                                                                                           | 0.9  | 0         |
| 490 | The effectiveness and safety of palbociclib and ribociclib in stage IV HR+/HER-2 negative breast cancer:<br>a nationwide real world comparative retrospective cohort study. Frontiers in Oncology, 0, 13, .                                                                                                                                  | 2.8  | 0         |
| 491 | The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment. Nature Reviews<br>Clinical Oncology, 2024, 21, 89-105.                                                                                                                                                                                                    | 27.6 | 4         |
| 492 | Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with<br>letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal<br>growth factor receptor-2 negative, locally advanced or metastatic breast cancer. European Journal<br>of Cancer, 2024, 198, 113480. | 2.8  | 0         |
| 493 | Patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a real-world study in Italy. Breast Cancer Management, 2023, 12, .                                                                                                                                                                                          | 0.2  | 0         |
| 494 | Firstâ€line CDK4/6 inhibitorâ€based combinations for HR+/HER2– advanced breast cancer: A Bayesian<br>network metaâ€analysis. Journal of Evidence-Based Medicine, 0, , .                                                                                                                                                                      | 1.8  | 0         |
| 495 | Ribociclib-induced liver injury: a case report. Frontiers in Oncology, 0, 13, .                                                                                                                                                                                                                                                              | 2.8  | 1         |
| 497 | Guidelines for diagnosis and treatment of advanced breast cancer in China (2022 edition)✰. Journal of the National Cancer Center, 2023, , .                                                                                                                                                                                                  | 7.4  | 0         |
| 498 | Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors. Therapeutic Advances in Medical Oncology, 2023, 15, .                                                                                                                      | 3.2  | 0         |

| #   | Article                                                                                                                                                                                                                                                         | IF  | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 499 | Aromatase inhibitors: the journey from the state of the art to clinical open questions. Frontiers in Oncology, 0, 13, .                                                                                                                                         | 2.8 | 0         |
| 500 | Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade:<br>Results of the GIM 13-AMBRA Study. Cancers, 2024, 16, 117.                                                                                                 | 3.7 | 0         |
| 501 | Targeted Therapies and Drug Resistance in Advanced Breast Cancer, Alternative Strategies and the Way beyond. Cancers, 2024, 16, 466.                                                                                                                            | 3.7 | 0         |
| 502 | A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer. BMC Medicine, 2024, 22, .                                        | 5.5 | 0         |
| 503 | Hormone, Targeted, and Combinational Therapies for Breast Cancers: From Humans to Dogs.<br>International Journal of Molecular Sciences, 2024, 25, 732.                                                                                                          | 4.1 | 0         |
| 504 | Relationship between Medication-Related Osteonecrosis of the Jaw and CDK4/6 Inhibitors in Breast Cancer. Current Oncology, 2024, 31, 250-259.                                                                                                                   | 2.2 | 2         |
| 505 | Realâ€world study of palbociclib combined with endocrine therapy for patients with metastatic breast<br>cancer: AÂcomparison of subsequent treatment patterns and HER2 expression analysis. Cancer, 2024,<br>130, 1476-1487.                                    | 4.1 | 1         |
| 506 | Research Progress in First-Line Treatment for Hormone Receptor-Positive/Human Epidermal Growth<br>Factor Receptor 2-Negative Advanced Breast Cancer. Advances in Clinical Medicine, 2024, 14, 397-402.                                                          | 0.0 | 0         |
| 507 | Somatic mutation: Pharmacogenomics in oncology care. , 2024, , 329-356.                                                                                                                                                                                         |     | 0         |
| 508 | The association between HER2-low status and survival in patients with metastatic breast cancer<br>treated with Cyclin-dependent kinases 4 andÂ6Âinhibitors: a systematic review and meta-analysis. Breast<br>Cancer Research and Treatment, 2024, 204, 443-452. | 2.5 | 1         |
| 509 | Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer. Clinical Pharmacokinetics, 2024, 63, 155-170.                                                                              | 3.5 | 0         |
| 510 | Experimental and clinical evidence in favour of an effective immune stimulation in ER-positive, endocrine-dependent metastatic breast cancer. Frontiers in Immunology, 0, 14, .                                                                                 | 4.8 | 0         |
| 511 | Somatic Mutations in Latin American Breast Cancer Patients: A Systematic Review and Meta-Analysis.<br>Diagnostics, 2024, 14, 287.                                                                                                                               | 2.6 | 0         |
| 512 | Therapies for the Treatment of Advanced/Metastatic Estrogen Receptor-Positive Breast Cancer:<br>Current Situation and Future Directions. Cancers, 2024, 16, 552.                                                                                                | 3.7 | 0         |
| 515 | Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer.<br>Journal of Oncology Pharmacy Practice, 2024, 30, 547-551.                                                                                                   | 0.9 | 0         |
| 516 | Real-world experience with CDK4-6 inhibition in the old and oldest old with a diagnosis of breast cancer. Seminars in Oncology, 2024, , .                                                                                                                       | 2.2 | 0         |
| 517 | Cardiovascular complications of ribociclib in breast cancer patients. Critical Reviews in Oncology/Hematology, 2024, 196, 104296.                                                                                                                               | 4.4 | 0         |
| 519 | Treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone<br>receptorâ€positive, <scp>HER2</scp> â€negative metastatic breast cancer: A realâ€world multicenter study.<br>Cancer Medicine, 2024, 13, .                   | 2.8 | 0         |
|     |                                                                                                                                                                                                                                                                 |     |           |

| #   | Article                                                                                                                                                                                                                                                            | IF   | CITATIONS |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 520 | A real-world pharmacovigilance study of QT interval prolongation and Torsades de Pointes<br>associated with CDK4/6 inhibitors in breast cancer patients: findings from the FDA adverse event<br>reporting system. Expert Opinion on Drug Safety, 0, , 1-8.         | 2.4  | 0         |
| 521 | Advances in Clinical Research on the CDK4/6 Inhibitors for HR+/HER2? Advanced Breast Cancer.<br>Advances in Clinical Medicine, 2024, 14, 458-466.                                                                                                                  | 0.0  | 0         |
| 523 | The effects of low HER2 expression on survival in patients with metastatic breast cancer treated with CDK 4/6 inhibitors: a multicenter retrospective study. Breast Cancer Research and Treatment, 0, , .                                                          | 2.5  | 0         |
| 524 | A Representative Clinical Course of Progression, with Molecular Insights, of Hormone<br>Receptor-Positive, HER2-Negative Bone Metastatic Breast Cancer. International Journal of Molecular<br>Sciences, 2024, 25, 3407.                                            | 4.1  | 0         |
| 525 | Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort. Clinical and Translational Oncology, 0, , .                                                                         | 2.4  | 0         |
| 526 | Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study. Lancet Oncology. The, 2024, 25, 474-487. | 10.7 | 0         |